Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cosmos Health (COSM) Capital Leases (2019 - 2025)

Cosmos Health's Capital Leases history spans 7 years, with the latest figure at $1788.0 for Q1 2025.

  • Quarterly results put Capital Leases at $1788.0 for Q1 2025, down 82.35% from a year ago — trailing twelve months through Mar 2025 was $1788.0 (down 82.35% YoY), and the annual figure for FY2024 was $3399.0, down 35.39%.
  • Capital Leases for Q1 2025 was $1788.0 at Cosmos Health, down from $3399.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $305250.0 in Q2 2023 to a low of $1788.0 in Q1 2025.
  • The 5-year median for Capital Leases is $139708.5 (2021), against an average of $119380.7.
  • The sharpest move saw Capital Leases soared 152.47% in 2021, then plummeted 97.77% in 2024.
  • Year by year, Capital Leases stood at $148401.0 in 2021, then plummeted by 78.89% to $31333.0 in 2022, then crashed by 83.21% to $5261.0 in 2023, then plummeted by 35.39% to $3399.0 in 2024, then plummeted by 47.4% to $1788.0 in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $1788.0, $3399.0, and $5845.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.